NAD+
Also called NAD+, NMN
Intravenous (into a vein)Human study reference
Research reference
Human study
IV NAD+ metabolome pilot
750 mg IV over 6 hours in the study group
Blood and urine measurements over 8 hours
Grant et al., Frontiers in Aging Neuroscience (2019) ↗When results may show
- When change was measured
- The study examined NAD metabolites, not sustained energy, addiction recovery, cognition or lifespan.
- When to assess
- Blood and urine measurements over 8 hours
- Conditions and limitations
- Small healthy-volunteer pilot. A single infusion pilot is not a weekly wellness course or evidence for oral/subcutaneous NAD+. Precursors such as NR/NMN are different interventions.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Loading the structure…
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Grant et al., Frontiers in Aging Neuroscience (2019)A single infusion pilot is not a weekly wellness course or evidence for oral/subcutaneous NAD+. Precursors such as NR/NMN are different interventions.